Curated News
By: NewsRamp Editorial Staff
May 18, 2026

Quantum BioPharma Hits Midpoint in MS Imaging Study with MGH

Discuss on Substack
Original Source

TLDR

  • Quantum BioPharma's MS imaging study halfway done; novel tracer may speed drug development, giving investors a potential edge.
  • The study uses [¹⁸F]3F4AP PET tracer to directly assess demyelination in MS lesions, with encouraging preliminary data.
  • This imaging technique could accelerate MS therapy development, improving lives for millions affected by multiple sclerosis.
  • The tracer detects gray matter lesions, a hard-to-spot MS feature, offering new insights into disease progression.

Impact - Why it Matters

This news matters because multiple sclerosis affects over 2.8 million people worldwide, and current imaging techniques often miss gray matter lesions, which are critical for disease progression. Quantum BioPharma's novel PET tracer could revolutionize MS diagnosis and treatment monitoring, potentially leading to more effective therapies like Lucid-MS. For investors, the study's positive signals and the company's strategic partnerships (including royalty streams from UNBUZZD) highlight a promising biotech opportunity in a high-need area.

Summary

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a significant milestone in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital, announcing that patient enrollment is now halfway complete. Preliminary imaging data from the study, which utilizes a novel PET imaging technique with the [¹⁸F]3F4AP tracer to directly assess demyelination, has shown encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions. This breakthrough could accelerate the development of MS therapies, including Quantum BioPharma's investigational candidate Lucid-MS, for which an IND submission for a Phase 2 trial was submitted to the FDA in March 2026. The study's progress underscores Quantum's commitment to addressing challenging neurodegenerative disorders through innovative biotech solutions.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is focused on Lucid-MS, a patented new chemical entity that has shown potential to prevent and reverse myelin degradation in preclinical models. Additionally, Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop pharmaceutical formulations based on the technology.

This news, disseminated on behalf of Quantum BioPharma, highlights the company's progress in MS research and its broader pipeline. For more details, the full press release is available at https://ibn.fm/4IZ0y. Investors can find the latest updates on QNTM in the company’s newsroom at https://ibn.fm/QNTM. The announcement was made through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, which provides enhanced press release distribution and corporate communications solutions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Hits Midpoint in MS Imaging Study with MGH

blockchain registration record for this content.